Status:

ACTIVE_NOT_RECRUITING

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Lead Sponsor:

SOLTI Breast Cancer Research Group

Collaborating Sponsors:

Novartis

Alliance Foundation Trials, LLC.

Conditions:

Metastatic Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (...

Eligibility Criteria

Inclusion

  • Main
  • Histologically documented HR-positive and HER2-negative breast cancer by local testing
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  • advanced (loco regionally recurrent not amenable to curative therapy or metastatic) breast cancer.
  • Availability of FFPE tumor block for biomarker analysis, obtained during metastatic period.
  • HER2-E or Basal-like subtype as per central PAM50 analysis.
  • Measurable disease or non-measurable disease, as defined by RECIST v1.1
  • Adequate hematologic and end-organ function
  • Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.
  • Women of childbearing potential must have confirmed negative serum pregnancy test within 7 days prior to randomization.
  • Women of CBP must be willing to use highly effective methods of contraception.
  • Patient must have a 6-lead or 12-lead ECG with ALL of the following parameters at screening:
  • QTcF interval (QT interval using Fridericia's correction) at screening \< 450 msec.
  • Resting heart rate 50-90 beats per minute (determined from the ECG).
  • Main

Exclusion

  • Prior therapy with any CDK4/6 inhibitors.
  • Patient has received prior treatment with chemotherapy for advanced/metastatic breast cancer

Key Trial Info

Start Date :

March 28 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2027

Estimated Enrollment :

456 Patients enrolled

Trial Details

Trial ID

NCT05207709

Start Date

March 28 2022

End Date

March 1 2027

Last Update

April 29 2025

Active Locations (71)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 18 (71 locations)

1

Morton Plant Hospital

Clearwater, Florida, United States, 33756

2

University of Miami

Coral Gables, Florida, United States, 33124

3

Memorial Regional Hospital

Hollywood, Florida, United States, 33021

4

Mount Sinai Florida

Miami, Florida, United States, 33140